Intelligence Search Intelligence Filter by: Industry Team Airport & AviationAutomotiveEmerging TechnologiesEnergy Food & BeverageHealth CareHospitality, Resort & GolfInsurance & Reinsurance Life SciencesMedical DevicesSports Practice Area Business Law All Business LawEmployee Benefits & Executive CompensationEnvironmental RegulationEstates & TrustsFinance & Financial InstitutionsHealth Care Finance Private Equity & Venture CapitalPublic FinanceReal EstateSecurities, Commodities & Exchange RegulationTaxationTransactional & Securities Government & Public Policy All Government & Public PolicyFDA RegulatoryGovernment ProcurementImmigration, Nationality & Consular Law NHTSA & Motor Vehicle SafetyPolitical LawPublic PolicySurface Transport Intellectual Property All Intellectual PropertyBusiness Method & Software PatentsChemical, Biotechnology & PharmaceuticalElectronicsGreen Energy TechnologiesInformation Technology & Outsourcing IP Due DiligenceIP LitigationMechanical & Electromechanical TechnologiesPatent Office TrialsTrademark, Copyright & Advertising Counseling International All InternationalChina EuropeJapan Litigation All LitigationAntitrustAppellateBankruptcy & Business ReorganizationsBusiness Litigation & Dispute ResolutionConstructionConsumer Financial Services Distribution & FranchiseGovernment Enforcement, Compliance & White Collar DefenseInsurance & Reinsurance LitigationLabor & EmploymentPrivacy, Security & Information ManagementSecurities Enforcement & LitigationTrade Secret Noncompete Litigation Topic Accountable Care OrganizationsAmerica Invents Act (Patent Reform)Consumer Protection Act Corporate GovernanceDodd–Frank Wall Street ReformExport Control/Economic Sanctions Foreign Corrupt Practices Act (FCPA)Health Care ReformPersonalized Medicine Type ArticleBlog Post BookNewsletter VideoWhite Paper Featured All Filters applied: Search phrase entered: Sort results by: Most Recent Most Viewed Most Shared Foley Blogs: CFSL Bulletin Cleantech & Nano Dashboard Insights Labor & Employment Law Perspectives Personalized Medicine Bulletin PharmaPatents Renewable Energy Outlook Wisconsin Appellate Law 12345next U.S. Supreme Court Agrees to Review Case That May Impact Patented Stem Cell Technologies 08 October 2012 Personalized Medicine Bulletin On October 5, 2012, the U.S. Supreme Court agreed to review the issue of whether the Federal Circuit erred by (1) refusing to find patent exhaustion that eliminates... Patent Pool Simplifies Development of Personalized Medicine 29 September 2012 Personalized Medicine Bulletin One argument often cited against patenting is that multiple patents can cover one product, its preparation and use, creating a so-called “patent thicket” that must... ACLU Petitions Supreme Court to Review Gene Patenting Case 25 September 2012 Personalized Medicine Bulletin The ACLU and PUBPAT issued a press release today announcing that they are petitioning the U.S. Supreme Court to review the U.S. Federal Circuit’s decision upholding... Federal Circuit Hands Personalized Medicine Patent Holders New Tool for Enforcement 06 September 2012 Personalized Medicine Bulletin If two or more actors jointly perform a patented method, is the claim infringed ? Late last week, in Akamai Technologies, Inc. v. Limelight Networks, Inc., and McKesson... En Banc Federal Circuit Eases Requirements for Induced Infringement of Method Claims 04 September 2012 PharmaPatents On August 31, 2012, the Federal Circuit issued an en banc, per curiam opinion deciding both Akamai Technologies, Inc. v. Limelight Networks, Inc. and McKesson Technologies,... Federal Stem Cell Funding Approved by Appellate Court 28 August 2012 Personalized Medicine Bulletin Good news for patients and stem cell researchers alike. On August 24th, the United States Courts of Appeals for the District of Columbia Circuit affirmed the District... Personalized Medicine After the ACLU "Gene Patenting" Decision 20 August 2012 Personalized Medicine Bulletin The biotechnology industry, including those investing in personalized medicine, have been waiting for the Federal Circuit’s decision that answers the questions whether... Deja Vu All Over Again in Federal Circuit's August 16 Myriad Decision 17 August 2012 PharmaPatents On August 16, 2012, just four weeks after it heard oral arguments, the Federal Circuit issued its second decision in Association for Molecular Pathology v. Myriad... More on Myriad — "Gene Patenting" Debate Continues 17 August 2012 Personalized Medicine Bulletin As promised in my earlier post, today our firm issued its review of the much anticipated decision regarding the “gene patenting” case (formally known... Federal Circuit – Non-Naturally DNA Patent-Eligible 16 August 2012 Personalized Medicine Bulletin Today, in Ass’n for Molecular Pathology v. Myriad Genetics, Inc., No. 2010-1406 (Fed. Cir. 2012), the Federal Circuit held that non-naturally occurring DNA... 12345next Related 1 2 3
U.S. Supreme Court Agrees to Review Case That May Impact Patented Stem Cell Technologies 08 October 2012 Personalized Medicine Bulletin On October 5, 2012, the U.S. Supreme Court agreed to review the issue of whether the Federal Circuit erred by (1) refusing to find patent exhaustion that eliminates...
Patent Pool Simplifies Development of Personalized Medicine 29 September 2012 Personalized Medicine Bulletin One argument often cited against patenting is that multiple patents can cover one product, its preparation and use, creating a so-called “patent thicket” that must...
ACLU Petitions Supreme Court to Review Gene Patenting Case 25 September 2012 Personalized Medicine Bulletin The ACLU and PUBPAT issued a press release today announcing that they are petitioning the U.S. Supreme Court to review the U.S. Federal Circuit’s decision upholding...
Federal Circuit Hands Personalized Medicine Patent Holders New Tool for Enforcement 06 September 2012 Personalized Medicine Bulletin If two or more actors jointly perform a patented method, is the claim infringed ? Late last week, in Akamai Technologies, Inc. v. Limelight Networks, Inc., and McKesson...
En Banc Federal Circuit Eases Requirements for Induced Infringement of Method Claims 04 September 2012 PharmaPatents On August 31, 2012, the Federal Circuit issued an en banc, per curiam opinion deciding both Akamai Technologies, Inc. v. Limelight Networks, Inc. and McKesson Technologies,...
Federal Stem Cell Funding Approved by Appellate Court 28 August 2012 Personalized Medicine Bulletin Good news for patients and stem cell researchers alike. On August 24th, the United States Courts of Appeals for the District of Columbia Circuit affirmed the District...
Personalized Medicine After the ACLU "Gene Patenting" Decision 20 August 2012 Personalized Medicine Bulletin The biotechnology industry, including those investing in personalized medicine, have been waiting for the Federal Circuit’s decision that answers the questions whether...
Deja Vu All Over Again in Federal Circuit's August 16 Myriad Decision 17 August 2012 PharmaPatents On August 16, 2012, just four weeks after it heard oral arguments, the Federal Circuit issued its second decision in Association for Molecular Pathology v. Myriad...
More on Myriad — "Gene Patenting" Debate Continues 17 August 2012 Personalized Medicine Bulletin As promised in my earlier post, today our firm issued its review of the much anticipated decision regarding the “gene patenting” case (formally known...
Federal Circuit – Non-Naturally DNA Patent-Eligible 16 August 2012 Personalized Medicine Bulletin Today, in Ass’n for Molecular Pathology v. Myriad Genetics, Inc., No. 2010-1406 (Fed. Cir. 2012), the Federal Circuit held that non-naturally occurring DNA...